outperform
reason report
account abbvi deal term move mp
bottom line decreas pt base
propos op deal term move
market perform outperform expect stock trade
base deal dynam longer fundament abbvi
announc week ago enter agreement
allergan acquir compani share price
cash stock deal intend close
term agreement allergan sharehold
receiv share cash allergan
share hold total consider
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep adjust ep fulli dilut
pleas refer page import disclosur price chart analyst certif
given acquisit agreement expect trade deal dynam
fundament deal expect close
pt base deal dynam
unlik instanc deal fail close current unforeseen reason
marc goodman certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori allergan plc
leerink place outperform rate juli
creat bluematrix
pt base deal dynam
risk valuat
unlik instanc deal fail close current unforeseen reason
rate price target histori abbvi inc
creat bluematrix
price target base simpl averag three approach believ reason
basi valu stock today approach simpl price earn multipl compar larg
biopharmaceut compani price sale multipl larg cap peer compani stock discount cash
flow dcf appli peer ep revenu multipl use averag larg cap larg molecul therapeut
compani mid-term growth tail risk celg averag consensu
ep multipl appli current ep estim give valu use
revenu multipl similar compani consensu sale appli revenu
estim give valu lastli dcf valuat given wacc termin
cash flow growth rate begin humira biosimilar entri give present valu averag
three method current price target upon complet analysi quarterli result
revisit price target present remain unchang
risk valuat
risk view outlook valuat includ major chang price outlook reimburs
coverag label competit posit humira compani main product risk includ commerci
develop disappoint compani follow-on program inflammatori diseas imbruvica
venclexta expand hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow dividend
reduct forecast ebitda due neg busi trend would place compani capit alloc
strategi dividend growth risk opportun upsid expect includ stronger-than-expect
price volum share humira emerg tangibl demand underappreci element
compani early-to-mid stage pipelin asset potenti label expans opportun late stage opportun
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
